|
| |
 |
| EDITORIAL |
|
| Year : 2016 | Volume
: 20
| Issue : 3 | Page : 283-284 |
|
The law of therapeutic parsimony
Sanjay Kalra1, Yashdeep Gupta2, Rakesh Sahay3
1 Department of Endocrinology, Bharti Hospital, Karnal, Haryana, India
2 Department of Endocrinology, All India Institute of Medical Sciences, New Delhi, India
3 Department of Endocrinology, Osmania Medical College, Hyderabad, Telangana, India
| Date of Web Publication | 11-Apr-2016 |
Correspondence Address:
Sanjay Kalra
Department of Endocrinology, Bharti Hospital, Karnal, Haryana
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/2230-8210.180008
How to cite this article:
Kalra S, Gupta Y, Sahay R. The law of therapeutic parsimony. Indian J Endocr Metab 2016;20:283-4 |
Modern diabetes care is characterized by an ever increasing number of pharmacological options. Treatment goals for various aspects of diabetes management, such as glycated hemoglobin (HbA1c), blood pressure, and lipids, have also become stringent.[1] This encourages polypharmacy and makes therapeutic decision-making a challenge. This challenge may enhance, instead of alleviate, clinical errors and clinical inertia.
One way of avoiding this is to use lesser pharmaceutical intervention wherever possible. We term this “The Law of Therapeutic Parsimony,” which states “minimal therapeutic interventions should be used, in place of multiple ones, as long as this can achieve equivalent therapeutic outcomes.”
According to the Law of Therapeutic Parsimony, the least required number of drugs, drug combinations, or drug preparations should be used, in the least required dose and frequency of dosing, to achieve predecided therapeutic outcomes. Therapeutic parsimony promotes safety and tolerability by reducing the risk of side effects, and facilitates adherence using less complex regimes, but does not compromise on efficiency.
The Law derives from Occam's razor, which states “pluralitas nonest ponenda sine necessitate” or “plurality must not be posited without necessity.”[2] It is also similar to the Law of Diagnostic Parsimony, which encourage identification of one diagnosis to explain multiple symptoms, sign and laboratory anomalies.[3] The Law of Diagnostic Parsimony is well-known to all students of medicine. A person presenting with a neck swelling, prominent eyes, and increased pulse rate, for example, is given a single diagnostic label of Graves' disease, rather than three diagnoses of goiter, exophthalmos, and tachycardia. From a diabetes perspective, diagnostic parsimony would prefer identification (and management) of diabetic nephropathy, rather than have separate approaches to coexistent anemia, hypertension, hyperglycemia, and reduced glomerular filtration rate.
Till recently, it has been difficult to apply the law of therapeutic parsimony to the field of diabetes care. More often than not, diabetes presents with other aspects of metabolic syndrome, which need simultaneous attention. Multiple drugs, with differing mechanisms of action, have been required to address the multiple pathophysiologic abnormalities present in diabetes and ensure comprehensive metabolic control.[4],[5]
Newer molecules, fixed dose combinations (FDCs), and fixed-ratio combinations, however, are now available and are apposite options for management of diabetes. Glucagon-like peptide-1 receptor agonists and sodium glucose co-transporter 2 inhibitors are able to achieve composite endpoints, including lowering of glucose, blood pressure, lipids, and weight.[6],[7] These drugs are relatively simple to use, often in a once daily dose, with minimal titration requirement, flexibility in timing of administration, and can be co-formulated with basal insulin and metformin. Insulin co-formulations and premixed analogs also offer comprehensive glycemic control, including lowering of fasting glucose, postprandial glucose, and HbA1c, in a safe and well-tolerated manner.
Such characteristics encourage greater adherence to therapy and facilitate achievement of optimal therapeutic outcomes. Drugs which achieve comprehensive glucometabolic modulation are, therefore, a welcome addition to the therapeutic landscape of diabetes. Their usage simplifies management plans, allows correction of multiple pathological anomalies, reduces the burden on pharmacies, and limits costs.
It is relatively easy, therefore, to put the Law of Therapeutic Parsimony into practice now. Use of co-formulations, premixed insulin, and oral FDCs can reduce injection frequency and pill burden for the patient. Prescription of rational combinations allows administration of lower doses of individual molecules, which reduces the possibility of adverse events, and enhances tolerability. Choice of modern drugs which offer broad spectrum glucometabolic control, including glucose, blood pressure, weight, and lipid control, helps facilitate this process.
We therefore suggest that the Law of Therapeutic Parsimony be included as a cardinal guiding principle of therapeutics in diabetology.
 References | |  |
| 1. | Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, et al. Consensus statement by the American association of clinical endocrinologists and American college of endocrinology on the comprehensive type 2 diabetes management algorithm-2016 executive summary. Endocr Pract 2016;22:84-113.  [ PUBMED] |
| 2. | Bleakley A. Blunting Occam's razor: Aligning medical education with studies of complexity. J Eval Clin Pract 2010;16:849-55. |
| 3. | Drachman DA. Dizziness among older adults: A possible geriatric syndrome. Ann Intern Med 2000;132:403-5. [ PUBMED] |
| 4. | Defronzo RA. Banting Lecture. From the triumvirate to the ominous octet: A new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009;58:773-95. |
| 5. | Schwartz SS, Epstein S, Corkey BE, Grant SF, Gavin JR 3 rd, Aguilar RB. The time is right for a new classification system for diabetes: Rationale and implications of the ß-cell-centric classification schema. Diabetes Care 2016;39:179-86. |
| 6. | Scheen AJ, Van Gaal LF. Combating the dual burden: Therapeutic targeting of common pathways in obesity and type 2 diabetes. Lancet Diabetes Endocrinol 2014;2:911-22. |
| 7. | Tahrani AA, Barnett AH, Bailey CJ. SGLT inhibitors in management of diabetes. Lancet Diabetes Endocrinol 2013;1:140-51. |
| This article has been cited by | | 1 |
Will the plant-based movement redefine physicians’ understanding of chronic disease? |
|
| Maximilian Andreas Storz | | The New Bioethics. 2020; 26(2): 141 | | [Pubmed] | [DOI] | | | 2 |
Diabetes in the Elderly |
|
| Sanjay Kalra,Suresh K. Sharma | | Diabetes Therapy. 2018; | | [Pubmed] | [DOI] | | | 3 |
Expert Opinion: Patient Selection for Premixed Insulin Formulations in Diabetes Care |
|
| Sanjay Kalra,Leszek Czupryniak,Gary Kilov,Roberta Lamptey,Ajay Kumar,A. G. Unnikrishnan,Aissa Boudiba,Mohamed Abid,Zhanay A. Akanov,Ali Latheef,Mustafa Araz,Ralph Audehm,Silver Bahendeka,Naby Balde,Sandeep Chaudhary,Chaicharn Deerochanawong,Olufemi Fasanmade,Hinde Iraqi,Tint Swe Latt,Jean Claude Mbanya,Joel Rodriguez-Saldana,Ko Seung Hyun,Zafar A. Latif,Maxim Lushchyk,Magdy Megallaa,Mohammed Wali Naseri,Nguyen Quang Bay,Kaushik Ramaiya,Hoosen Randeree,Syed Abbas Raza,Khalid Shaikh,Dina Shrestha,Eugene Sobngwi,Noel Somasundaram,Norlela Sukor,Rima Tan | | Diabetes Therapy. 2018; | | [Pubmed] | [DOI] | | | 4 |
Switching from Biphasic Human Insulin to Premix Insulin Analogs: A Review of the Evidence Regarding Quality of Life and Adherence to Medication in Type 2 Diabetes Mellitus |
|
| Nabil El Naggar,Sanjay Kalra | | Advances in Therapy. 2016; | | [Pubmed] | [DOI] | |
|
 |
|
|
|
